Ticagrelor (BRILINTA®) is a very commonly used oral antiplatelet agent in acute coronary syndrome and after percutaneous coronary intervention (PCI). It is a reversible, direct inhibitor of the adenosine diphosphate (ADP) P2Y12 receptor. Most of the patients tolerate the drug well but it is known to cause brady arrhythmias and ventricular pauses, the exact mechanism of which is unclear. We present a case of acute coronary syndrome/unstable angina in a 58-year-old Caucasian gentleman requiring cardiac catheterization and PCI with drug eluting stent deployment and syncope following Ticagrelor loading from long ventricular pauses.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899257PMC
http://dx.doi.org/10.7759/cureus.12874DOI Listing

Publication Analysis

Top Keywords

acute coronary
8
ventricular pauses
8
ticagrelor-induced syncope/bradyarrhythmia
4
syncope/bradyarrhythmia ticagrelor
4
ticagrelor brilinta®
4
brilinta® commonly
4
commonly oral
4
oral antiplatelet
4
antiplatelet agent
4
agent acute
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!